Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03741-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Carlo Messina und 36 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, A.R.N.A.S. Civico Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Firenze.
Abstract (Originalsprache)
Background
Although nivolumab prolongs overall survival (OS) in pretreated patients with metastatic renal cell carcinoma (mRCC), underlining clinical and biological features of long-term responses are still to be determined. This study aims to investigate clinical and pathological characteristics of mRCC patients who achieved long-term responses during nivolumab treatment. Materials and methods A retrospective analysis was performed on mRCC patients receiving nivolumab as second or further therapy line between May 2016 and January 2019 in 34 Italian Oncology Centres. Outcome assessments and logistic regression were performed to evaluate factors influencing long-term responses.
Results
A total of 571 patients with a median age of 61 years (range 17–85) were included in the analysis. With a median follow-up of 22.1 (1.0–89.0) months, 23.1% of patients were 2-year progression-free on treatment with nivolumab, hence they were categorized as long-term responders. Baseline characteristics, including age, gender, and histology, were similar between long- and short-term responders. Karnofsky Performance Status ≥ 80% was significantly associated with long-term response ( p = 0.02), while bone metastases ( p = 0.03), International mRCC Database Consortium intermediate-poor risk ( p < 0.01) and Neutrophil-to-Lymphocyte Ratio ≥ 3.2 ( p = 0.02) were associate with short-term responses. Long-term responders exhibited a median progression-free survival of 55.0 months versus 4.0 months of the short-term responders. The median OS was not reached in long-term responders while it was 17.0 months for short*term responders.
Conclusion
This retrospective analysis sheds light on factors associated with long-term response to nivolumab in mRCC. Understanding these clinical features will be essential for selecting patients who may mostly benefit from immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Unit, A.R.N.A.S. Civico Palermo, Palermo, Italy.
- Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy.
- Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. giandomenico.roviello@unifi.it.
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino of Genova, Genova, Italy.
- Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
- Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Förderung
- Università degli Studi di Firenze
Zitieren
APA
Messina, C., Catalano, M., Roviello, G., Gandini, A., Maruzzo, M., De Giorgi, U., Pedrazzoli, P., Sbrana, A., Zucal, P. A., Masini, C., Naglieri, E., Procopio, G., Milella, M., Catalano, F., Fratino, L., Pipitone, S., Ricotta, R., Panni, S., Mollica, V., …, & Fornarini, G. (2024). Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03741-2
Vancouver
Messina C, Catalano M, Roviello G, Gandini A, Maruzzo M, De Giorgi U, et al. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03741-2
BibTeX
@article{Messina2024,
author = {Messina, Carlo and Catalano, Martina and Roviello, Giandomenico and Gandini, Annalice and Maruzzo, Marco and De Giorgi, Ugo and Pedrazzoli, Paolo and Sbrana, Andrea and Zucal, Paolo Andrea and Masini, Cristina and Naglieri, Emanuele and Procopio, Giuseppe and Milella, Michele and Catalano, Fabio and Fratino, Lucia and Pipitone, Stefania and Ricotta, Riccardo and Panni, Stefano and Mollica, Veronica and Soraru, Mariella and Prati, Veronica and Atzori, Francesco and Di Napoli, Marilena and Messina, Marco and Morelli, Franco and Prati, Giuseppe and Nole, Franco and Malgeri, Andrea and Tudini, Marianna and Vignani, Francesca and Cavo, Alessia and Signori, Alessio and Banna, Giuseppe Luigi and Rescigno, Pasquale and Buti, Sebastiano and Rebuzzi, Sara Elena and Fornarini, Giuseppe},
title = {Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03741-2}
}
EUVIMED